- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03053024
Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in Chinese Participants
November 5, 2020 updated by: Xian-Janssen Pharmaceutical Ltd.
An Observational Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in China
The purpose of the study (retrospective and prospective) is to describe participant and disease characteristics and treatment pattern of Bortezomib treated mantle cell lymphoma (MCL) participants in China.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
54
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China, 100021
- Cancer Hospital, Chinese Academy of Medical Sciences
-
Beijing, China, 100142
- Peking University Cancer Hospital
-
Changchun, China, 130021
- The First Hospital of Jilin University
-
Changsha, China, 410008
- Xiangya Hospital Central South University
-
Guangzhou, China, 510515
- Nanfang Hospital
-
NanJing, China, 210029
- Jiangsu Province Hospital
-
Shanghai, China, 200025
- Ruijin Hospital, Shanghai Jiao Tong University
-
Shanghai, China, 200040
- Huashan Hospital Fudan University
-
Tianjin, China, 300020
- Blood disease hospital of Chinese Academy of Medical Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Study include mantle cell lymphoma (MCL) participants who were or will be treated by Bortezomib (BTZ) per routine clinical care in multiple tertiary care hospitals after January 1st 2009.
Both newly diagnosed MCL participants and relapsed/refractory MCL participants will be included.
Description
Inclusion Criteria:
- Participants that have been hospitalized for MCL after January 1st 2009.
- Biopsy proven MCL as evidenced by histology with either immunohistochemistry (IHC) or t(11,14) translocation
- Retrospective group: Participants who have finished BTZ treatment before the study initiation as judged by participating site physician
- If participant isn't accessible for oral or written informed consent, ICF can be waived after approved by the IRB
- Prospective group: Participants who are on BTZ at the time of study initiation or start BTZ after study initiation
Exclusion Criteria:
- Participants with documented diagnosis of other cancers prior to or at the presence of the diagnosis of MCL
- Participants enrolled in interventional clinical trials of BTZ or any other drug for MCL
- Prospective group: Participants with contraindication listed in the prescribing information of BTZ
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Cohort 1: Relapse/refractory MCL (rrMCL ) Participants
Participants characteristics and treatment pattern of relapsed/refractory mantel cell lymphoma [rrMCL]) participants treated by Bortezomib (BTZ) will be observed for cohort 1.
|
Cohort 2: Newly Diagnosed MCL Participants
Participants characteristics and treatment pattern of newly diagnosed MCL participants (if more than 20% of total BTZ-treated MCL) will be analysed for cohort 2.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Demographic Characteristic of Participants in Prospective Group: Age
Time Frame: Baseline
|
Continuous variable (age) will be summarized using descriptive statistics.
|
Baseline
|
Participants Disease Status (newly diagnosed MCL or relapsed/refractory mantel cell lymphoma [rrMCL]) Treated With BTZ
Time Frame: Baseline
|
Categorical variable (disease status) will be summarized using a frequency distribution with the number and percentage of participants in each category.
Treatment response will be analyzed by this variable if newly diagnosed MCL patients account for more than 20 percent (%) of total.
|
Baseline
|
Eastern Cooperative Oncology Group (ECOG) Performance Status
Time Frame: Baseline
|
A worsening in Eastern Cooperative Oncology Group (ECOG) performance status score was defined as greater than or equal to 1-point increase from Baseline.
ECOG is a 5-point scale 0=Fully active, 1=Ambulatory, carry out work of sedentary nature, 2=Ambulatory, capable of all self-care, 3=Capable of limited self-care, confined to bed or chair more than 50% of waking hours, 4=Completely disabled, no self-care, totally confined to bed or chair, 5=Dead.
|
Baseline
|
Ann Arbor Stage
Time Frame: Up to Follow-up (approximately 22 months)
|
Ann Arbor stage can be obtained from imaging results or directly from admission records.
Ann Arbor stage describes areas of involvement; Stage I(IE) - One lymph node region or extralymphatic site (IE); Stage II(IIE)- Two or more lymph node regions or at least one lymph node region plus a single localized extralymphatic site (IIE) on the same side of the diaphragm; stage III (IIIE, IIIS)-Lymph node regions or lymphoid structures (example, thymus,Waldeyer's ring) on both sides of the diaphragm with optional localised extranodal site (IIIE) or spleen (IIIS); stage IV-Diffuse or disseminated extralymphatic organ involvement.
|
Up to Follow-up (approximately 22 months)
|
Prognostic Index Score
Time Frame: Baseline
|
Prognostic index will be summarized using descriptive statistics.
For each prognostic factor, 0-3 points are given to each patient and points are summed up to a maximum of 11.
Participants with 0-3 points are classified as low risk (44% of participants, median overall survival [OS] not reached).
Participants with 4-5 points are classified as intermediate risk (35%, median OS 51 months), and patients with 6-11 points as high risk (21%, median OS 29 months).
|
Baseline
|
Demographic Characteristic of Participants in Prospective Group: Gender
Time Frame: Baseline
|
Categorical variable (gender) will be summarized using a frequency distribution with the number and percentage of participants in each category.
|
Baseline
|
Treatment pattern of BTZ-treated MCL participants: Route of Administration
Time Frame: Up to Follow-up (approximately 22 months)
|
Primary MCL therapy with Velcade (BTZ) prior MCL treatment, combined MCL treatment and subsequent MCL treatment to extract the information on route of administration (subcutaneous [SC] or intravenous [IV]) to see if there's any outstanding factor that impacts BTZ's dose/frequency and identify the most popular usage of BTZ.
|
Up to Follow-up (approximately 22 months)
|
Treatment Pattern of Bortezomib (BTZ) Treated MCL participants: Dose
Time Frame: Up to Follow-up (approximately 22 months)
|
The cumulated dose will be summarized using descriptive statistics.
|
Up to Follow-up (approximately 22 months)
|
Treatment Pattern of Bortezomib (BTZ) Treated MCL Participants: Frequency
Time Frame: Up to Follow-up (approximately 22 months)
|
The frequency of BTZ will be summarized using a frequency distribution with the number and percentage of participants in each category.
|
Up to Follow-up (approximately 22 months)
|
Treatment Pattern of Bortezomib (BTZ) Treated MCL Participants: Reason of BTZ Initiation/Discontinuation/Dose Adjustment
Time Frame: Up to Follow-up (approximately 22 months)
|
The reason of BTZ initiation/discontinuation/dose adjustment will be described with respective number of occurrence.
|
Up to Follow-up (approximately 22 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: Approximately 22 months
|
ORR is defined as the sum of complete response [CR] rate (CR+ unconfirmed complete remission [CRu]) + Partial remission [PR] rate as per International Working Group (IWG 2007) criteria.
These response criteria are based on the reduction in the size of the enlarged lymph node as measured by computerized tomography (CT) scan and the extent of bone marrow involvement that is determined by bone marrow aspirate and biopsy.
Complete response [CR] defined as disappearance of all evidence of disease; CRu satisfies CR criteria, however any residual lymph node mass greater than (>)1.5 centimeter (cm) in longest transverse dimension or extranodal site of disease (irrespective of size) must have regressed by more than 75% of the product of the longest perpendicular dimensions compared to the pretreatment baseline.
PR defined as at least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses.
|
Approximately 22 months
|
Complete Response [CR] Rate (CR+ Unconfirmed Complete Remission CRu)
Time Frame: Approximately 22 months
|
The percentage of participants with CR and CRu in all participants whose treatment response data are available.
|
Approximately 22 months
|
Partial Remission (PR) Rate
Time Frame: Approximately 22 months
|
The percentage of participants with PR in all participants whose treatment response data are available.
|
Approximately 22 months
|
Time to Response (TTR)
Time Frame: Approximately 22 months
|
Interval between start of treatment to the first day when CR/CRu or PR was observed.
|
Approximately 22 months
|
Duration of Response (DOR)
Time Frame: Approximately 22 months
|
Interval from the date the response was documented to the first day that Progressive Disease (PD) was observed in participants with CR/CRu or PR.
PD defined as any new lesions or increase by greater than or equal to (>=) 50% of previously involved sites from nadir.
|
Approximately 22 months
|
Progressive-Free Survival (PFS)
Time Frame: Approximately 22 months
|
Interval between start of treatment to first day when death or PD was observed.
PD defined as any new lesions or increase by >= 50% of previously involved sites from nadir.
|
Approximately 22 months
|
Overall survival (OS)
Time Frame: Approximately 22 months
|
Interval from the day of the start of the treatment to death, or the last date when the participant was identified to be alive whichever is late.
|
Approximately 22 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
April 14, 2017
Primary Completion (ACTUAL)
September 30, 2019
Study Completion (ACTUAL)
September 30, 2019
Study Registration Dates
First Submitted
February 10, 2017
First Submitted That Met QC Criteria
February 10, 2017
First Posted (ACTUAL)
February 14, 2017
Study Record Updates
Last Update Posted (ACTUAL)
November 6, 2020
Last Update Submitted That Met QC Criteria
November 5, 2020
Last Verified
November 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR108287
- 26866138MCL4001 (OTHER: Xian-Janssen Pharmaceutical Ltd., China)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, Mantle-Cell
-
Northwestern UniversityNational Cancer Institute (NCI); Janssen Scientific Affairs, LLCActive, not recruitingStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Mantle Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)CompletedStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Stage I Mantle Cell Lymphoma | Stage II Contiguous Mantle Cell Lymphoma | Stage II Non-Contiguous Mantle Cell LymphomaUnited States
-
University of WashingtonNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma | Ann Arbor Stage I Mantle Cell Lymphoma | Ann Arbor Stage II Mantle Cell Lymphoma | Ann Arbor Stage III Mantle Cell Lymphoma | Ann Arbor Stage IV Mantle Cell LymphomaUnited States
-
Burzynski Research InstituteWithdrawnRecurrent Mantle Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell LymphomaUnited States
-
BeiGeneRecruitingMantle Cell Lymphoma | Relapsed Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma (MCL)United States, China, Israel, Belgium, Poland, Spain, Turkey, Brazil, Italy, Canada, United Kingdom, France, Germany, Argentina
-
BeiGeneCompletedRefractory Mantle Cell Lymphoma | Relapsed Mantle Cell LymphomaChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMantle Cell Lymphoma | Blastoid Variant Mantle Cell Lymphoma | Pleomorphic Variant Mantle Cell LymphomaUnited States
-
Fondazione Italiana Linfomi - ETSRecruitingRefractory Mantle Cell Lymphoma | Relapsed Mantle Cell LymphomaItaly